Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Security

RDPTF · Radiopharm Theranostics Ltd

RDPTFOTCCommon stockCurrentCIK 1949257Updated Sep 24, 2026

Company: Radiopharm Theranostics Ltd

RDPTF price & chart

Provider market data

Loading TradingView…

OTC:RDPTF on TradingView ↗

TradingView · Data may be delayed

In the news

No coverage from other publishers is available.

Seeking Alpha
SEC disclosures

Recent filings

  1. EFFECT filing

    EFFECT · 2026-09-23 · 9999999995-26-003045

  2. 424B3 filing

    424B3 · 2026-09-23 · 0001213900-26-102669

  3. 6-K filing

    6-K · 2026-09-22 · 0001213900-26-101968

  4. 6-K filing

    6-K · 2026-09-14 · 0001213900-26-099435

  5. F-3 filing

    F-3 · 2026-09-14 · 0001213900-26-099432

Show 5 more recent filings
  1. 6-K filing

    6-K · 2026-09-11 · 0001213900-26-098976

  2. 6-K filing

    6-K · 2026-09-09 · 0001213900-26-098219

  3. 6-K filing

    6-K · 2026-08-28 · 0001213900-26-094655

  4. 6-K filing

    6-K · 2026-08-27 · 0001213900-26-094127

  5. 6-K filing

    6-K · 2026-08-26 · 0001213900-26-093730

Financials

FY 2025 · USD
Revenue3,633,422USD · FY 2025
Source

20-F · 2025-09-18 · 0001213900-25-088699

2024-07-01 to 2025-06-30

Net income · FY 2025
AssetsUSD · FY 2025
Cash · FY 2025
Operating income-38,173,865USD · FY 2025
Source

20-F · 2025-09-18 · 0001213900-25-088699

2024-07-01 to 2025-06-30

Diluted EPS-1.76USD per share · FY 2025
Source

20-F · 2025-09-18 · 0001213900-25-088699

2024-07-01 to 2025-06-30

Some figures are unavailable for this reporting year.

Balance-sheet figures are unavailable pending verification.

cash flow · annual statements
Line itemFY 2025
Cash flows from operating activities:
Profit or LossUSD-38,342,457
Source

20-F · 2025-09-18 · 0001213900-25-088699

2024-07-01 to 2025-06-30

Additional Financial Items
AdjustmentsForFinanceCostsUSD-285
Source

20-F · 2025-09-18 · 0001213900-25-088699

2024-07-01 to 2025-06-30

AdjustmentsForFinanceIncomeUSD-888,196
Source

20-F · 2025-09-18 · 0001213900-25-088699

2024-07-01 to 2025-06-30

AdjustmentsForSharebasedPaymentsUSD1,895,348
Source

20-F · 2025-09-18 · 0001213900-25-088699

2024-07-01 to 2025-06-30

AdjustmentsForUnrealisedForeignExchangeLossesGainsUSD-138,141
Source

20-F · 2025-09-18 · 0001213900-25-088699

2024-07-01 to 2025-06-30

GeneralAndAdministrativeExpenseUSD14,638,013
Source

20-F · 2025-09-18 · 0001213900-25-088699

2024-07-01 to 2025-06-30

InterestReceivedClassifiedAsOperatingActivitiesUSD800,309
Source

20-F · 2025-09-18 · 0001213900-25-088699

2024-07-01 to 2025-06-30

ProceedsFromIssuingSharesUSD53,977,902
Source

20-F · 2025-09-18 · 0001213900-25-088699

2024-07-01 to 2025-06-30

Lines labelled “Derived” are calculated from reported figures.

income statement · annual statements
Line itemFY 2025
Cost of Goods and Services Sold
Total RevenueUSD3,633,422
Source

20-F · 2025-09-18 · 0001213900-25-088699

2024-07-01 to 2025-06-30

Additional Financial Items
BasicEarningsLossPerShareUSD per share-1.76
Source

20-F · 2025-09-18 · 0001213900-25-088699

2024-07-01 to 2025-06-30

CurrentTaxExpenseIncomeUSD103,292
Source

20-F · 2025-09-18 · 0001213900-25-088699

2024-07-01 to 2025-06-30

DilutedEarningsLossPerShareUSD per share-1.76
Source

20-F · 2025-09-18 · 0001213900-25-088699

2024-07-01 to 2025-06-30

FinanceCostsUSD65,300
Source

20-F · 2025-09-18 · 0001213900-25-088699

2024-07-01 to 2025-06-30

GeneralAndAdministrativeExpenseUSD14,638,013
Source

20-F · 2025-09-18 · 0001213900-25-088699

2024-07-01 to 2025-06-30

GrossProfitUSD39,276
Source

20-F · 2025-09-18 · 0001213900-25-088699

2024-07-01 to 2025-06-30

IncomeTaxExpenseContinuingOperationsUSD103,292
Source

20-F · 2025-09-18 · 0001213900-25-088699

2024-07-01 to 2025-06-30

OtherIncomeUSD10,256,740
Source

20-F · 2025-09-18 · 0001213900-25-088699

2024-07-01 to 2025-06-30

ProfitLossBeforeTaxUSD-38,239,165
Source

20-F · 2025-09-18 · 0001213900-25-088699

2024-07-01 to 2025-06-30

ProfitLossFromOperatingActivitiesUSD-38,173,865
Source

20-F · 2025-09-18 · 0001213900-25-088699

2024-07-01 to 2025-06-30

ResearchAndDevelopmentExpenseUSD27,515,194
Source

20-F · 2025-09-18 · 0001213900-25-088699

2024-07-01 to 2025-06-30

Lines labelled “Derived” are calculated from reported figures.

Filing attachments

ea030617901ex99-1.htm · 6-K · 2026-09-22

Exhibit 99.1 Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001. Amended 01/01/11 Name Radiopharm of Entity: Theranostics Limited (ASX: RAD) ABN: 57 647 877 889 We (the entity) give ASX th

6-K · 2026-09-22 · 0001213900-26-101968

Read attachment ↗